

# Salvatore Brugaletta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/404456/publications.pdf>

Version: 2024-02-01

309  
papers

9,848  
citations

50566

48  
h-index

49824

91  
g-index

331  
all docs

331  
docs citations

331  
times ranked

8840  
citing authors

#	ARTICLE	IF	CITATIONS
1	Angio-Based Fractional Flow Reserve, Functional Pattern of Coronary Artery Disease, and Prediction of Percutaneous Coronary Intervention Result: a Proof-of-Concept Study. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 645-653.	1.3	17
2	Mid-term effects of SARS-CoV-2 infection on cardiovascular outcomes. <i>Medicina Clínica</i> , 2022, 158, 41-42.	0.3	1
3	Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial. <i>European Heart Journal</i> , 2022, 43, 1320-1330.	1.0	26
4	Three-year results of ST-segment elevation myocardial infarction patients treated with a prespecified bioresorbable vascular scaffold implantation strategy: bVS STEMI STRATEGY-IT long-term. <i>Journal of Cardiovascular Medicine</i> , 2022, 23, 278-280.	0.6	1
5	Vascular Injury After Stenting—Insights of Systemic Mechanisms of Vascular Repair. <i>Circulation Journal</i> , 2022, 86, 966-974.	0.7	3
6	Mid-term effects of SARS-CoV-2 infection on cardiovascular outcomes. <i>Medicina Clínica (English)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.1	1
7	Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design. <i>American Heart Journal</i> , 2022, 246, 32-43.	1.2	1
8	Coronary Microvascular Angina: A State-of-the-Art Review. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 800918.	1.1	6
9	Ten-year patterns of stent thrombosis after percutaneous coronary intervention with new- versus early-generation drug-eluting stents: insights from the DECADE cooperation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2022, , .	0.4	5
10	Magnesium-based resorbable scaffold vs permanent metallic sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction: 3-year results of the MAGSTEMI randomised controlled trial. <i>EuroIntervention</i> , 2022, 18, e389-e396.	1.4	9
11	Procedural outcomes of the 34-mm EvolutR Transcatheter valve in a real-world population insights from the HORSE multicenter collaborative registry. <i>International Journal of Cardiology</i> , 2022, , .	0.8	2
12	Role of Quantitative Flow Ratio in Predicting Future Cardiac Allograft Vasculopathy in Heart Transplant Recipients. <i>Circulation: Cardiovascular Interventions</i> , 2022, 15, e011656.	1.4	1
13	Amphilimus- versus everolimus-eluting stents in patients with diabetes mellitus: 5-year follow-up of the RESERVOIR trial. <i>Cardiovascular Revascularization Medicine</i> , 2022, , .	0.3	0
14	Circulating miRNA Fingerprint and Endothelial Function in Myocardial Infarction: Comparison at Acute Event and One-Year Follow-Up. <i>Cells</i> , 2022, 11, 1823.	1.8	4
15	Two-year outcomes after percutaneous coronary intervention with drug-eluting stents or bare-metal stents in elderly patients with coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E607-E613.	0.7	0
16	The importance of organizational variables in treatment time for patients with ST-elevation acute myocardial infarction improve delays in STEMI. <i>Australasian Emergency Care</i> , 2021, 24, 141-146.	0.7	2
17	Longitudinal Neointimal Distribution Pattern After Everolimus-Eluting Stent Implantation: Insights From Optical Coherence Tomography Study. <i>Cardiovascular Revascularization Medicine</i> , 2021, 26, 17-23.	0.3	2
18	Percutaneous Treatment of a Circumflex Artery Occlusion After Minimally Invasive Barlow Disease Mitral Valve Repair. <i>JACC: Case Reports</i> , 2021, 3, 173-176.	0.3	6

#	ARTICLE	IF	CITATIONS
19	Coronary endothelial and microvascular function distal to polymer-free and endothelial cell-capturing drug-eluting stents. The randomized FUNCOMBO trial. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 1013-1022.	0.4	4
20	Pulmonary ridge coverage and device-related thrombosis after left atrial appendage occlusion. <i>EuroIntervention</i> , 2021, 16, e1288-e1294.	1.4	26
21	Second generation drug-eluting stents: a focus on safety and efficacy of current devices. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 107-127.	0.6	4
22	10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1165-1178.	1.2	32
23	Surgical Risk Scoring in TAVR: Still Needed? A Metaregression Analysis. <i>Current Problems in Cardiology</i> , 2021, 46, 100875.	1.1	4
24	Función endotelial y microvascular distal a stents farmacoactivos sin polímero y captadores de células endoteliales. Estudio aleatorizado FUNCOMBO. <i>Revista Espanola De Cardiologia</i> , 2021, 74, 1014-1023.	0.6	2
25	Impact of diabetes mellitus on vascular healing process after everolimus-eluting stent implantation: An optical coherence tomography study. <i>Cardiovascular Revascularization Medicine</i> , 2021, , .	0.3	1
26	Myocardial Injury in COVID-19 Patients: Association with Inflammation, Coagulopathy and In-Hospital Prognosis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2096.	1.0	17
27	Alcohol Septal Ablation: An Option on the Rise in Hypertrophic Obstructive Cardiomyopathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 2276.	1.0	9
28	EAPCI Core Curriculum for Percutaneous Cardiovascular Interventions (2020): Committee for Education and Training European Association of Percutaneous Cardiovascular Interventions (EAPCI). A branch of the European Society of Cardiology.. <i>EuroIntervention</i> , 2021, 17, 23-31.	1.4	4
29	Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial. <i>Circulation</i> , 2021, 143, 2143-2154.	1.6	16
30	May LAAO Learning Curve Explain the Relationship Between Procedural Volume and Complications Rate?. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1263-1264.	1.1	0
31	Impact of chronic kidney disease in chronic total occlusion management and clinical outcomes. <i>Cardiovascular Revascularization Medicine</i> , 2021, , .	0.3	3
32	The "RotaTripsy Plus" Approach in a Heavily Calcified Coronary Stenosis. <i>Cardiovascular Revascularization Medicine</i> , 2021, 28, 203-205.	0.3	5
33	Long-term vascular function in CTO recanalization: A randomized clinical trial of ticagrelor vs. clopidogrel. <i>Cardiovascular Revascularization Medicine</i> , 2021, , .	0.3	0
34	Long-term effects of coronavirus disease 2019 on the cardiovascular system, CV COVID registry: A structured summary of a study protocol. <i>PLoS ONE</i> , 2021, 16, e0255263.	1.1	12
35	New Interventional Therapies beyond Stenting to Treat ST-Segment Elevation Acute Myocardial Infarction. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 100.	0.8	5
36	Horizontal Aorta in Transcatheter Self-Expanding Valves: Insights From the HORSE International Multicentre Registry. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010641.	1.4	12

#	ARTICLE	IF	CITATIONS
37	Aortic angle distribution and predictors of horizontal aorta in patients undergoing transcatheter aortic valve replacement. <i>International Journal of Cardiology</i> , 2021, 338, 58-62.	0.8	4
38	Initial Results after the Implementation of an Edge-To-Edge Transcatheter Tricuspid Valve Repair Program. <i>Journal of Clinical Medicine</i> , 2021, 10, 4252.	1.0	7
39	Acute and Chronic Effects of COVID-19 on the Cardiovascular System. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 128.	0.8	16
40	Low Dose of Direct Oral Anticoagulants after Left Atrial Appendage Occlusion. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 142.	0.8	11
41	Treatment of device related thrombosis after left atrial appendage occlusion: Initial experience with low-dose apixaban. <i>Cardiovascular Revascularization Medicine</i> , 2021, , .	0.3	0
42	Coronary Endotheliumâ€Dependent Vasomotor Function After Drugâ€Eluting Stent and Bioresorbable Scaffold Implantation. <i>Journal of the American Heart Association</i> , 2021, 10, e022123.	1.6	4
43	Clinical Impact of Medical Therapy Versus Revascularization in Patients With Chronic Coronary Total Occlusions. <i>Journal of Invasive Cardiology</i> , 2021, 33, E2-E8.	0.4	1
44	Endothelial Progenitor Cell Function in Patients With Coronary Chronic Total Occlusion and its Relationship With Collateral Circulation. <i>Journal of Invasive Cardiology</i> , 2021, 33, E809-E816.	0.4	1
45	The Role of Antiplatelet Therapy in Patients With MINOCA. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 821297.	1.1	7
46	607â€Comparison of incidence and predictors of new left bundle branch block and permanent pacemaker implantation in a large multicentre contemporary TAVI registry using the Evolut R/pro system vs. the accurate neo valve. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	1
47	612â€Comparison of two self-expandable supra-annular bioprosthesis: a propensity score-matched analysis. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
48	599â€Gender-based differences in TAVI outcomes: report from a large contemporary real-world population of self-expandable valves. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
49	Lipid plaque burden in NSTEMI-ACS patients with or without COPD: insights from the SCAP Trial. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 738-745.	0.4	1
50	597â€Comparison between low versus intermediate-high risk patients in a contemporary real-world multicentre TAVI registry using self-expanding supra-annular valves: a propensity score matched analysis. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
51	595â€Impact of age on outcomes in a large multicentre low-to-intermediate risk TAVI population: in and out the age cut-off from ESC 2021 valvular heart disease guidelines. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
52	Outcomes of Nonagenarians With ST Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2020, 125, 11-18.	0.7	17
53	Validation of the all-comers design: Results of the TARGET-AC substudy. <i>American Heart Journal</i> , 2020, 221, 148-154.	1.2	0
54	TCT CONNECT-7 Everolimus-Eluting Stent Versus Bare-Metal Stent in ST-Segment Elevation Myocardial Infarction: 10-Year Follow-Up of the Multicenter Randomized Controlled Examination Trial. <i>Journal of the American College of Cardiology</i> , 2020, 76, B4.	1.2	2

#	ARTICLE	IF	CITATIONS
55	Response by Ortega-Paz et al to Letter Regarding Article, "Magnesium-Based Resorbable Scaffold Versus Permanent Metallic Sirolimus-Eluting Stent in Patients With ST-Segment Elevation Myocardial Infarction: The MAGSTEMI Randomized Clinical Trial" Circulation, 2020, 141, e748-e749.	1.6	0
56	Very-late restenosis of a magnesium-based resorbable scaffold. European Heart Journal, 2020, 41, 2602-2602.	1.0	1
57	Randomized Comparison of Optical Coherence Tomography Versus Angiography to Guide Bioresorbable Vascular Scaffold Implantation: The OPTICO BVS Study. Cardiovascular Revascularization Medicine, 2020, 21, 1244-1250.	0.3	6
58	Durable polymer everolimus-eluting stents: history, current status and future prospects. Expert Review of Medical Devices, 2020, 17, 671-682.	1.4	3
59	Sex-based differences in chronic total occlusion management and long-term clinical outcomes. International Journal of Cardiology, 2020, 319, 46-51.	0.8	11
60	STEMI With a Massive Coronary Aneurysm. JACC: Case Reports, 2020, 2, 477-479.	0.3	3
61	Comparison of clinical outcomes in STEMI patients treated with primary PCI according to day-time of medical attention and its relationship with circadian pattern. International Journal of Cardiology, 2020, 305, 35-41.	0.8	3
62	Ticagrelor or Prasugrel in Acute Coronary Syndromes. New England Journal of Medicine, 2020, 382, 486-487.	13.9	0
63	Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) trial: Rationale and study design. American Heart Journal, 2020, 222, 174-182.	1.2	7
64	Disparate miRNA expression in serum and plasma of patients with acute myocardial infarction: a systematic and paired comparative analysis. Scientific Reports, 2020, 10, 5373.	1.6	58
65	Coronary vasomotor function and myocardial flow with bioresorbable vascular scaffolds or everolimus-eluting metallic stents: a randomised trial. EuroIntervention, 2020, 16, e155-e163.	1.4	7
66	Bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ST-segment elevation myocardial infarction: 5-year results of the BVS-EXAMINATION study. EuroIntervention, 2020, 15, 1436-1443.	1.4	13
67	Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction: vascular healing outcomes from the MAGSTEMI trial. EuroIntervention, 2020, 16, e913-e921.	1.4	16
68	Comparison of Major Adverse Cardiac Events Between Instantaneous Wave-Free Ratio and Fractional Flow Reserve-Guided Strategy in Patients With or Without Type 2 Diabetes. JAMA Cardiology, 2019, 4, 857.	3.0	25
69	Sex Differences in Instantaneous Wave-Free Ratio or Fractional Flow Reserve-Guided Revascularization Strategy. JACC: Cardiovascular Interventions, 2019, 12, 2035-2046.	1.1	26
70	TCT-256 Minimally Invasive Transradial Approach for Percutaneous Closure of Aortic Paravalvular Leaks: A Single-Center Experience. Journal of the American College of Cardiology, 2019, 74, B255.	1.2	0
71	TCT-483 Influence of Multivessel Disease and Impact of Complete Revascularization in Left Ventricular Function Recovery Following STEMI. Journal of the American College of Cardiology, 2019, 74, B478.	1.2	0
72	Use of an Arteriovenous Loop to Facilitate Transcatheter Aortic Valve Alignment in a Patient With Giant Ascending Aortic Aneurysm. JACC: Cardiovascular Interventions, 2019, 12, 1863-1864.	1.1	1

#	ARTICLE	IF	CITATIONS
73	Cost-Effectiveness of Drug-Eluting Stents in Elderly Patients With Coronary Artery Disease: The SENIOR Trial. <i>Value in Health</i> , 2019, 22, 1355-1361.	0.1	3
74	TCT-287 Impact of Eligibility Criteria on Clinical Outcomes of Firehawk and XIENCE Coronary Drug-Eluting Stent in an All-Comers Randomized Trial. <i>Journal of the American College of Cardiology</i> , 2019, 74, B286.	1.2	0
75	Does Large Vessel Size Justify Use of Bare-Metal Stents in Primary Percutaneous Coronary Intervention?. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007705.	1.4	6
76	Magnesium-Based Resorbable Scaffold Versus Permanent Metallic Sirolimus-Eluting Stent in Patients With ST-Segment Elevation Myocardial Infarction. <i>Circulation</i> , 2019, 140, 1904-1916.	1.6	74
77	Prognostic Value of QFR Measured Immediately After Successful Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2079-2088.	1.1	103
78	Clinical Events After Deferral of LAD Revascularization Following Physiological Coronary Assessment. <i>Journal of the American College of Cardiology</i> , 2019, 73, 444-453.	1.2	35
79	View point on social media use in interventional cardiology. <i>Open Heart</i> , 2019, 6, e001031.	0.9	13
80	2-Year Clinical Outcomes of an Abluminal Groove-Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1679-1687.	1.1	14
81	Long-term impact of diabetes in patients with ST-segment elevation myocardial infarction: Insights from the EXAMINATION randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 917-925.	0.7	5
82	Transcatheter Aortic Valve Replacement With Next-Generation Self-Expanding Devices. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 433-443.	1.1	59
83	How to SORT OUT an Additional Value From Noninferiority Stent Comparisons?. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 634-636.	1.1	0
84	Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2572-2584.	1.2	31
85	Magnesium-based bioresorbable scaffold and vasomotor function in patients with acute ST segment elevation myocardial infarction: The MAGSTEMI trial: Rationale and design. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 64-70.	0.7	10
86	A serial 3- and 9-year optical coherence tomography assessment of vascular healing response to sirolimus- and paclitaxel-eluting stents. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 9-21.	0.7	2
87	The influence of Elixhauser comorbidity index on percutaneous coronary intervention outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 195-203.	0.7	14
88	Baseline Risk Stratification of Patients Older Than 75 Years With Infarction and Cardiogenic Shock Undergoing Primary Angioplasty. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2019, 72, 1005-1011.	0.4	0
89	Thrombocytopenia after transcatheter aortic valve implantation. A comparison between balloon-expandable and self-expanding valves. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 1344-1351.	0.7	11
90	One-Year Results Following a Pre-Specified ABSORB Implantation Strategy in ST-Elevation Myocardial Infarction (BVS STEMI STRATEGY-IT Study). <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 700-704.	0.3	6



#	ARTICLE	IF	CITATIONS
91	Cell-free DNA and Microvascular Damage in ST-segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2019, 72, 317-323.	0.4	7
92	Impact of sex on comparative outcomes of bivalirudin versus unfractionated heparin in patients with acute coronary syndromes undergoing invasive management: a pre-specified analysis of the MATRIX trial. <i>EuroIntervention</i> , 2019, 15, e269-e278.	1.4	2
93	Coronary artery lesion phenotype in frail older patients with non-ST-elevation acute coronary syndrome undergoing invasive care. <i>EuroIntervention</i> , 2019, 15, e261-e268.	1.4	19
94	Clinical, Angiographic, and Procedural Correlates of Very Late Absorb Scaffold Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 638-644.	1.1	20
95	Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006023.	1.4	80
96	Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION) <i>Tj ETQq0 0 0 rg BT /Overlock 10 Tf</i> <i>Cardiology</i> , 2018, 121, 1039-1045.	0.7	10
97	Análisis morfológico y funcional de la arteria descendente anterior de pacientes con síndrome de tako-tsubo. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 986-988.	0.6	3
98	Antithrombotic Therapy in Acute Coronary Syndrome: Striking a Happy Medium. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2018, 71, 782-786.	0.4	2
99	Effects of Ticagrelor, Prasugrel, or Clopidogrel at Steady State on Endothelial Function. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1289-1291.	1.2	13
100	Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1231-1242.	1.2	32
101	Angina and Ischemia at 2 Years With Bioresorbable Vascular Scaffolds and Metallic Drug-eluting Stents. ESTROFA Ischemia BVS-mDES Study. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2018, 71, 327-334.	0.4	1
102	False Positive STEMI Activations in a Regional Network: Comprehensive Analysis and Clinical Impact. Results From the Catalanian Codi Infart Network. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2018, 71, 243-249.	0.4	9
103	Ticagrelor and Absorb bioresorbable vascular scaffold implantation for recovery of vascular function after successful chronic total occlusion recanalization (TIGER-BVS trial): Rationale and study design. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 1-6.	0.7	6
104	Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. <i>Lancet, The</i> , 2018, 391, 41-50.	6.3	307
105	Functional and Morphological Assessment of Left Anterior Descending Artery in Patients With Tako-tsubo Syndrome. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2018, 71, 986-988.	0.4	2
106	Multivessel disease in patients over 75 years old with ST elevated myocardial infarction. Current management strategies and related clinical outcomes in the ESTROFA MI + 75 nation-wide registry. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 580-588.	0.3	5
107	Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the European Multicentre GHOST-EU Registry. <i>Catheterization and Cardiovascular Interventions</i> . 2018. 91. 444-453.	0.7	8
108	Thrombectomy and Stroke. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1597-1599.	1.2	4

#	ARTICLE	IF	CITATIONS
109	TCT-869 Two years outcomes in elderly patients planned for one-month DAPT after PCI: subanalysis of the SENIOR trial. <i>Journal of the American College of Cardiology</i> , 2018, 72, B346.	1.2	0
110	Latest STEMI treatment: a focus on current and upcoming devices. <i>Expert Review of Medical Devices</i> , 2018, 15, 807-817.	1.4	11
111	Targeted therapy with a localised abluminal groove, low-dose sirolimus-eluting, biodegradable polymer coronary stent (TARGET All Comers): a multicentre, open-label, randomised non-inferiority trial. <i>Lancet, The</i> , 2018, 392, 1117-1126.	6.3	46
112	Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1576-1586.	1.1	43
113	Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1559-1571.	1.1	29
114	Fractional Flow Reserve Derived From Computed Tomographic Angiography in Patients With Multivessel CAD. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2756-2769.	1.2	92
115	Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea. <i>Circulation</i> , 2018, 138, 646-648.	1.6	35
116	Ticagrelor versus clopidogrel for recovery of vascular function immediately after successful chronic coronary total occlusion recanalization: A randomized clinical trial. <i>American Heart Journal</i> , 2018, 204, 205-209.	1.2	4
117	Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1437-1449.	1.1	111
118	Impact of PSP Technique on Clinical Outcomes Following Bioresorbable Scaffolds Implantation. <i>Journal of Clinical Medicine</i> , 2018, 7, 27.	1.0	10
119	Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial. <i>PLoS ONE</i> , 2018, 13, e0201985.	1.1	3
120	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. <i>Lancet, The</i> , 2018, 392, 835-848.	6.3	215
121	Association between coronary atherosclerosis progression and in-stent neoatherosclerosis in patients with ST-elevation myocardial infarction at five-year follow-up. <i>EuroIntervention</i> , 2018, 14, 206-214.	1.4	3
122	How should I treat a bioresorbable vascular scaffold edge restenosis and intra-scaffold dissection?. <i>EuroIntervention</i> , 2018, 13, 1730-1734.	1.4	1
123	First serial optical coherence tomography assessment at baseline, 12 and 24 months in STEMI patients treated with the second-generation Absorb bioresorbable vascular scaffold. <i>EuroIntervention</i> , 2018, 13, 2201-2209.	1.4	6
124	Functional comparison between the BuMA Supreme biodegradable polymer sirolimus-eluting stent and a durable polymer zotarolimus-eluting coronary stent using quantitative flow ratio: PIONEER QFR substudy. <i>EuroIntervention</i> , 2018, 14, e570-e579.	1.4	24
125	First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial. <i>EuroIntervention</i> , 2018, 13, 2026-2035.	1.4	17
126	Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: insights from five-year follow-up of the EXAMINATION trial. <i>EuroIntervention</i> , 2018, 13, 1939-1945.	1.4	7



#	ARTICLE	IF	CITATIONS
127	Quality difference of neointima following the implantation of everolimus-eluting bioresorbable scaffolds and metallic stents in patients with ST-elevation myocardial infarction: quantitative assessments by light intensity, light attenuation, and backscatter on optical coherence tomography in the TROFI II trial. <i>EuroIntervention</i> , 2018, 14, 678-685.	1.4	12
128	Impact of SGLT2i on cardiovascular outcomes and heart failure in patients with type 2 diabetes. <i>AIMS Medical Science</i> , 2018, 5, 67-79.	0.2	1
129	Moving fast towards the future: the role of #SoMe in learning cardiology. <i>EuroIntervention</i> , 2018, 13, 1874-1875.	1.4	3
130	Angioplastia primaria en mayores de 75 años. Perfil de pacientes y procedimientos, resultados y predictores pronósticos en el registro ESTROFA IM + 75. <i>Revista Española De Cardiología</i> , 2017, 70, 81-87.	0.6	25
131	Endothelial function impairment in STEMI patients with out-of-hospital cardiac arrest under therapeutic hypothermia treatment. <i>International Journal of Cardiology</i> , 2017, 232, 70-75.	0.8	5
132	A longer look at trial evidence of bioresorbable vascular scaffolds. <i>Heart</i> , 2017, 103, 1061-1062.	1.2	2
133	Out-of-hospital cardiac arrest and stent thrombosis: Ticagrelor versus clopidogrel in patients with primary percutaneous coronary intervention under mild therapeutic hypothermia. <i>Resuscitation</i> , 2017, 114, 141-145.	1.3	30
134	Bioresorbable Everolimus-Eluting Vascular Scaffold for Long Coronary Lesions. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 560-568.	1.1	16
135	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2592-2603.	1.2	132
136	CLINICAL, ANGIOGRAPHIC AND PROCEDURAL CORRELATES OF ABSORB SCAFFOLD THROMBOSIS: A MATCHED MULTICENTER REGISTRY ANALYSIS. <i>Journal of the American College of Cardiology</i> , 2017, 69, 964.	1.2	1
137	A NEW PROGNOSIS SCORE TO PREDICT MORTALITY IN PATIENTS OVER 75 YEARS OLD UNDERGOING PRIMARY ANGIOPLASTY IN CARDIOGENIC SHOCK. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1278.	1.2	0
138	Rationale and design of the Hunting for the off-target properties of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial. <i>American Heart Journal</i> , 2017, 189, 128-136.	1.2	8
139	Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. <i>New England Journal of Medicine</i> , 2017, 376, 1824-1834.	13.9	742
140	Clinical, Angiographic, and Procedural Correlates of Acute, Subacute, and Late Absorb Scaffold Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1809-1815.	1.1	26
141	A Prospective Evaluation of a Pre-Specified Absorb BVS Implantation Strategy in ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1855-1864.	1.1	22
142	Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1867-1877.	1.1	13
143	Percutaneous Treatment of Extremely Small Coronary Vessels. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1389-1391.	1.1	3
144	Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation. <i>American Journal of Cardiology</i> , 2017, 120, 1460-1466.	0.7	20

#	ARTICLE	IF	CITATIONS
145	TCT-128 Relationship between bioresorbable vascular scaffold technique and acute recoil. Journal of the American College of Cardiology, 2017, 70, B57.	1.2	0
146	A prospective evaluation of a standardized strategy for the use of a polymeric everolimus-eluting bioresorbable scaffold in ST-segment elevation myocardial infarction: Rationale and design of the BVS STEMI STRATEGY study. Catheterization and Cardiovascular Interventions, 2017, 89, 1129-1138.	0.7	9
147	Primary Angioplasty in Patients Older Than 75 Years. Profile of Patients and Procedures, Outcomes, and Predictors of Prognosis in the ESTROFA IM + 75 Registry. Revista Espanola De Cardiologia (English) Tj ETQq1 10.7843141ngBT /O	0.7	18
148	Three-dimensional printing of an aortic model for transcatheter aortic valve implantation: possible clinical applications. International Journal of Cardiovascular Imaging, 2017, 33, 283-285.	0.7	18
149	Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: Insights from the European multicenter GHOST-EU registry. Catheterization and Cardiovascular Interventions, 2017, 89, 812-818.	0.7	15
150	Cost-effectiveness of percutaneous coronary intervention with cobalt-chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta-analysis of randomized trials. Catheterization and Cardiovascular Interventions, 2017, 89, 994-1002.	0.7	9
151	Serial optical coherence tomography assessment of malapposed struts after everolimus-eluting stent implantation. A subanalysis from the HEAL-EES study. Cardiovascular Revascularization Medicine, 2017, 18, 47-52.	0.3	1
152	TCT-564 Monocenter registry of 1248 consecutive patients with a coronary chronic total occlusion: predictor factors of cardiac death. Journal of the American College of Cardiology, 2017, 70, B233-B234.	1.2	1
153	Methods to assess bioresorbable vascular scaffold devices behaviour after implantation. Journal of Thoracic Disease, 2017, 9, S959-S968.	0.6	4
154	Bioresorbable scaffolds: should we stay simple or go complex?. Cardiovascular Diagnosis and Therapy, 2017, 7, E7-E12.	0.7	0
155	miRNA Update: A Review Focus on Clinical Implications of miRNA in Vascular Remodeling. AIMS Medical Science, 2017, 4, 99-112.	0.2	5
156	Selective use of contemporary drug-eluting stents in primary angioplasty for ST-elevation myocardial infarction: pooled analysis of COMFORTABLE AMI and EXAMINATION. EuroIntervention, 2017, 12, 1577-1586.	1.4	3
157	A randomised trial of paclitaxel-eluting balloon after bare metal stent implantation vs. bare metal stent in ST-elevation myocardial infarction (the PEBSI study). EuroIntervention, 2017, 12, 1587-1594.	1.4	11
158	Impact of stent overlapping on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction: insights from the five-year follow-up of the EXAMINATION trial. EuroIntervention, 2017, 13, e557-e563.	1.4	8
159	Twelve-month outcomes after bioresorbable vascular scaffold implantation in patients with acute coronary syndromes. Data from the European Multicenter GHOST-EU Extended Registry. EuroIntervention, 2017, 13, e1104-e1111.	1.4	9
160	Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score. EuroIntervention, 2017, 12, 2110-2117.	1.4	114
161	Data from real-world registries: can it guide development of the bioresorbable scaffolds of tomorrow?. EuroIntervention, 2017, 13, 1259-1262.	1.4	2
162	Propensity-matched comparison of percutaneous and surgical cut-down approaches in transfemoral transcatheter aortic valve implantation using a balloon-expandable valve. Moving to the percutaneous approach. EuroIntervention, 2017, 13, 1365-1366.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Bioresorbable vascular scaffolds technology: current use and future developments. <i>Medical Devices: Evidence and Research</i> , 2016, Volume 9, 185-198.	0.4	8
164	Puncture Versus Surgical Cutdown Complications of Transfemoral Aortic Valve Implantation (from) <i>Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50</i>	0.7	19
165	TCT-404 ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-year results from a propensity score matched comparison. <i>Journal of the American College of Cardiology</i> , 2016, 68, B164.	1.2	0
166	TCT-419 Usefulness of a scoring system for predicting adverse cardiovascular events in patients undergoing everolimus-eluting bioresorbable scaffolds implantation: the PSP score. <i>Journal of the American College of Cardiology</i> , 2016, 68, B169-B170.	1.2	2
167	ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-Year results from a propensity score matched comparison. <i>International Journal of Cardiology</i> , 2016, 214, 483-484.	0.8	20
168	Could Plaque Composition-Related Endothelial Dysfunction Predict Poor Prognosis in Coronary Vasospastic Angina?. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1867.	1.2	0
169	Unfavorable bioresorbable vascular scaffold resorption, a cause of restenosis?. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 571-573.	0.3	1
170	Five-Year Optical Coherence Tomography in Patients With ST-Segmentâ€Elevation Myocardial Infarction Treated With Bare-Metal Versus Everolimus-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	22
171	Sharing Data from Cardiovascular Clinical Trials â€” A Proposal. <i>New England Journal of Medicine</i> , 2016, 375, 407-409.	13.9	49
172	Can new generation P2Y12 inhibitors play a role in microvascular obstruction in STEMI?. <i>International Journal of Cardiology</i> , 2016, 223, 226-227.	0.8	4
173	Letter by Garcia-Garcia and Brugaletta Regarding Article, â€œOptical Coherence Tomographyâ€Guided Percutaneous Coronary Intervention in ST-Segmentâ€Elevation Myocardial Infarction: A Prospective Propensity-Matched Cohort of the Thrombectomy Versus Percutaneous Coronary Intervention Alone Trialâ€• <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	0
174	Safety of glycoprotein IIb/IIIa inhibitors in patients under therapeutic hypothermia admitted for an acute coronary syndrome. <i>Resuscitation</i> , 2016, 106, 108-112.	1.3	13
175	TCT-120 Primary angioplasty for patients over 75 years old in cardiogenic shock: contemporary results and prognostic predictors from the ESTROFA MI+75 nationwide registry. <i>Journal of the American College of Cardiology</i> , 2016, 68, B48.	1.2	0
176	Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. <i>BMJ, The</i> , 2016, 354, i4935.	3.0	43
177	The Role of Virtual Histology Intravascular Ultrasound in the Identification of Coronary Artery Plaque Vulnerability in Acute Coronary Syndromes. <i>Cardiology in Review</i> , 2016, 24, 303-309.	0.6	18
178	Overtime evaluation of the vascular HEALing process after everolimus-eluting stent implantation by optical coherence tomography. The HEAL-EES study. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 241-247.	0.3	9
179	Optical coherence tomography: A pathway from research to clinical practice. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 71-73.	0.3	0
180	Minimally Invasive Transradial Percutaneous Closure of Aortic Paravalvular Leaks: Following the Steps of Percutaneous Coronary Intervention. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1575.e17-1575.e19.	0.8	4

#	ARTICLE	IF	CITATIONS
181	Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarctionâ€”TROFI II trial. <i>European Heart Journal</i> , 2016, 37, 229-240.	1.0	197
182	A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 42-50.	1.1	68
183	1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 440-449.	1.1	23
184	Bioresorbable Scaffold vs. Second Generation Drug Eluting Stent in Long Coronary Lesions requiring Overlap: A Propensity-Matched Comparison (the UNDERDOGS study). <i>International Journal of Cardiology</i> , 2016, 208, 40-45.	0.8	32
185	Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. <i>Lancet, The</i> , 2016, 387, 357-366.	6.3	174
186	Levosimendan as an adjunctive therapy to MitraClip implantation in patients with severe mitral regurgitation and left ventricular dysfunction. <i>International Journal of Cardiology</i> , 2016, 202, 517-518.	0.8	13
187	Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised TROFI II study. <i>EuroIntervention</i> , 2016, 12, 482-489.	1.4	25
188	Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry. <i>EuroIntervention</i> , 2016, 12, e550-e556.	1.4	32
189	Bioresorbable vascular scaffolds in clinical practice: state-of-the-art. <i>Panminerva Medica</i> , 2016, 58, 130-42.	0.2	2
190	Late Right Coronary Ostium Occlusion After Percutaneous Aortic Paravalvular Leak Closure: Immediate Results Do Not Always Predict Long-Term Performance. <i>Journal of Invasive Cardiology</i> , 2016, 28, E69-70.	0.4	2
191	ST-Segment Elevation Myocardial Infarction. <i>Circulation Journal</i> , 2015, 79, 263-270.	0.7	16
192	Letter by Ortega-Paz et al Regarding Article, â€œEast Asian Variant of Aldehyde Dehydrogenase 2 Is Associated With Coronary Spastic Angina: Possible Roles of Reactive Aldehydes and Implications of Alcohol Flushing Syndromeâ€. <i>Circulation</i> , 2015, 132, e382.	1.6	0
193	Bioresorbable drug-eluting stent implantation technique: In search of a magic recipe. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 439-440.	0.3	1
194	A 12â€”month angiographic and optical coherence tomography followâ€”up after bioresorbable vascular scaffold implantation in patients with STâ€”segment elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, E180-9.	0.7	17
195	Bioresorbable vascular scaffold implantation in acute coronary syndromes: clinical evidence, tips and tricks. <i>Postepy W Kardiologii Interwencyjnej</i> , 2015, 3, 161-169.	0.1	9
196	Absorb Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent in ST-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity Score Matching Comparison. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 189-197.	1.1	145
197	Frequency and predictors of thrombus inside the guiding catheter during interventional procedures: an optical coherence tomography study. <i>International Journal of Cardiovascular Imaging</i> , 2015, 31, 239-246.	0.7	8
198	Platelet reactivity assessment with VerifyNowâ„®: Substitute or complement for light transmission aggregometry?. <i>International Journal of Cardiology</i> , 2015, 178, 221-222.	0.8	0

#	ARTICLE	IF	CITATIONS
199	Ventricular Restoration: New Therapeutic Approaches. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 257-259.	0.4	1
200	Sex-related Impact on Clinical Outcome of Everolimus-eluting Versus Bare-metal Stents in ST-segment Myocardial Infarction. Insights From the EXAMINATION Trial. <i>Revista Espanola De Cardiologia (English)</i> Tj ETQq0 0 0 r g BT / Overlock 10 T		
201	Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. <i>Lancet, The</i> , 2015, 385, 2465-2476.	6.3	1,043
202	Very Late Scaffold Thrombosis. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1901-1914.	1.2	186
203	Reproducibility of intravascular ultrasound radiofrequency data analysis (virtual histology) with a 45-MHz rotational imaging catheter in ex vivo human coronary arteries. <i>Journal of Cardiology</i> , 2015, 65, 134-142.	0.8	9
204	Everolimus-eluting stent versus bare-metal stent in elderly (>=75years) versus non-elderly (<75years) patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the examination trial. <i>International Journal of Cardiology</i> , 2015, 179, 73-78.	0.8	17
205	Radial Versus Femoral Access for Angioplasty of ST-segment Elevation Acute Myocardial Infarction With Second-generation Drug-eluting Stents. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 47-53.	0.4	5
206	Percutaneous Transcatheter Aortic Valve Implantation: A Review Focus on Outcomes and Safety. <i>AIMS Medical Science</i> , 2015, 2, 200-221.	0.2	3
207	Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials. <i>EuroIntervention</i> , 2015, 11, 391-398.	1.4	12
208	Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective. <i>EuroIntervention</i> , 2015, 11, 45-52.	1.4	131
209	Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. <i>BMJ, The</i> , 2014, 349, g6427-g6427.	3.0	82
210	Determinants of high cardiovascular risk in relation to plaque-composition of a non-culprit coronary segment visualized by near-infrared spectroscopy in patients undergoing percutaneous coronary intervention. <i>European Heart Journal</i> , 2014, 35, 282-289.	1.0	19
211	Reproducibility of intravascular ultrasound iMAP for radiofrequency data analysis: Implications for design of longitudinal studies. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, E233-42.	0.7	10
212	Coronary evaginations are associated with positive vessel remodelling and are nearly absent following implantation of newer-generation drug-eluting stents: an optical coherence tomography and intravascular ultrasound study. <i>European Heart Journal</i> , 2014, 35, 795-807.	1.0	67
213	Randomized Comparison Between Polymer-Free Versus Polymer-Based Paclitaxel-Eluting Stent. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 312-321.	1.4	15
214	Qualitative and quantitative accuracy of ultrasound-based virtual histology for detection of necrotic core in human coronary arteries. <i>International Journal of Cardiovascular Imaging</i> , 2014, 30, 469-476.	0.7	23
215	Distal side-branch technique: A new use for the Tornus® Catheter. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 97-99.	0.3	1
216	Comparison of Newer-Generation Drug-Eluting With Bare-Metal Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 55-63.	1.1	96



#	ARTICLE	IF	CITATIONS
217	TCT-221 Coronary Chronic Total Occlusions and Elderly: Clinical Profile And Prognosis. Journal of the American College of Cardiology, 2014, 64, B65.	1.2	0
218	Acute myocardial infarction, primary percutaneous coronary intervention and stent thrombosis in heart transplanted patient: Potential role of elevated coagulation factor VIII. Cor Et Vasa, 2014, 56, e311-e315.	0.1	0
219	The EXAMINATION Trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation) Tj ETQq1 1 0,784314 rgBT /Ove	1.1	80
220	Coronary Kinking in a Marathon Runner: A "Dangerous Liaison"? Revista Espanola De Cardiologia (English Ed ), 2014, 67, 767.	0.4	0
221	Waiting time prioritisation for specialist services in Italy: The homogeneous waiting time groups approach. Health Policy, 2014, 117, 54-63.	1.4	21
222	Impact of therapeutic hypothermia on coronary flow. International Journal of Cardiology, 2014, 172, 228-229.	0.8	6
223	Tortuosidad arterial coronaria en un corredor de marat3n: ¿una "relaci3n peligrosa"? Revista Espanola De Cardiologia, 2014, 67, 767.	0.6	0
224	Optimization in Stent Implantation by Manual Thrombus Aspiration in ST-Segment "Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2014, 7, 294-300.	1.4	30
225	Nitric-oxide Coated Bioactive Titanium Stents: Safer and More Effective Than Second-generation Drug-eluting Stents?. Revista Espanola De Cardiologia (English Ed ), 2014, 67, 511-513.	0.4	0
226	Assessment of Plaque Composition by Intravascular Ultrasound and Near-Infrared Spectroscopy. Circulation Journal, 2014, 78, 1531-1539.	0.7	19
227	Acute Absorb bioresorbable vascular scaffold thrombosis in ST-segment elevation myocardial infarction: to stent or not to stent?. EuroIntervention, 2014, 10, 600-600.	1.4	14
228	Lumen enlargement of the coronary segments located distal to chronic total occlusions successfully treated with drug-eluting stents at follow-up. EuroIntervention, 2014, 9, 1181-1188.	1.4	33
229	Does manual thrombus aspiration help optimize stent implantation in ST-segment elevation myocardial infarction?. World Journal of Cardiology, 2014, 6, 1030.	0.5	5
230	Cardiac embolism after implantable cardiac defibrillator shock in non-anticoagulated atrial fibrillation: The role of left atrial appendage occlusion. World Journal of Cardiology, 2014, 6, 213.	0.5	0
231	Can the vicious cycle of obscure or intractable gastrointestinal bleeding be broken in patients with atrial fibrillation subject to anticoagulant therapy?. Revista Espanola De Enfermedades Digestivas, 2014, 106, 350-3.	0.1	0
232	Drug eluting stent implantation in patients requiring concomitant vitamin K antagonist therapy. One-year outcome of the worldwide e-SELECT registry. International Journal of Cardiology, 2013, 168, 2522-2527.	0.8	1
233	First experience of a bioresorbable vascular scaffold implantation in left main stenosis. International Journal of Cardiology, 2013, 168, 1566-1568.	0.8	13
234	Reproducibility of qualitative assessment of stent struts coverage by optical coherence tomography. International Journal of Cardiovascular Imaging, 2013, 29, 5-11.	0.7	16



#	ARTICLE	IF	CITATIONS
235	Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 168, 2632-2636.	0.8	11
236	Three-dimensional optical frequency domain imaging in conventional percutaneous coronary intervention: the potential for clinical application. <i>European Heart Journal</i> , 2013, 34, 875-885.	1.0	54
237	Percutaneous transcatheter aortic valve implantation: present and future perspective. <i>Expert Review of Medical Devices</i> , 2013, 10, 185-199.	1.4	7
238	One-year head to head comparison of the neointimal response between sirolimus eluting stent with reservoir technology and everolimus eluting stent. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, E428-36.	0.7	6
239	Medical management of connector pin thrombosis with the Amplatzer cardiac plug left atrial closure device. <i>World Journal of Cardiology</i> , 2013, 5, 391.	0.5	5
240	Transcatheter aortic valve implantation in patients with left main percutaneous coronary intervention. <i>Journal of Heart Valve Disease</i> , 2013, 22, 874-7.	0.5	2
241	Long-Term (>10 Years) Clinical Outcomes of First-in-Human Biodegradable Poly-L-lactic Acid Coronary Stents. <i>Circulation</i> , 2012, 125, 2343-2353.	1.6	209
242	Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy?. <i>European Heart Journal</i> , 2012, 33, 1325-1333.	1.0	138
243	Vascular Compliance Changes of the Coronary Vessel Wall After Bioresorbable Vascular Scaffold Implantation in the Treated and Adjacent Segments. <i>Circulation Journal</i> , 2012, 76, 1616-1623.	0.7	57
244	Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. <i>Lancet</i> , The, 2012, 380, 1482-1490.	6.3	412
245	Analysis of 1-year virtual histology changes in coronary plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. <i>International Journal of Cardiovascular Imaging</i> , 2012, 28, 1307-1314.	0.7	13
246	Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: Can the scaffold cap the plaque?. <i>Atherosclerosis</i> , 2012, 221, 106-112.	0.4	115
247	Darapladib effect on circulating high sensitive troponin in patients with acute coronary syndromes. <i>Atherosclerosis</i> , 2012, 225, 142-147.	0.4	7
248	Lipid core burden index and Framingham score: Can a Systemic Risk Score predict lipid core burden in non-culprit coronary artery?. <i>International Journal of Cardiology</i> , 2012, 156, 211-213.	0.8	4
249	Everolimus-eluting ABSORB bioresorbable vascular scaffold: present and future perspectives. <i>Expert Review of Medical Devices</i> , 2012, 9, 327-338.	1.4	19
250	Endothelial Function in Coronary Chronic Total Occlusions. <i>Journal of the American College of Cardiology</i> , 2012, 60, 871-872.	1.2	2
251	Endothelial and Smooth Muscle Cells Dysfunction Distal to Recanalized Chronic Total Coronary Occlusions and the Relationship With the Collateral Connection Grade. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 170-178.	1.1	39
252	Differences in Neointimal Thickness Between the Abluminal and the Abluminal Sides of Malapposed and Side-Branch Struts in a Polylactide Bioresorbable Scaffold. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 428-435.	1.1	34

#	ARTICLE	IF	CITATIONS
253	Vascular Response of the Segments Adjacent to the Proximal and Distal Edges of the ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold: 6-Month and 1-Year Follow-Up Assessment. JACC: Cardiovascular Interventions, 2012, 5, 656-665.	1.1	35
254	A Global Risk Approach to Identify Patients With Left Main or 3-Vessel Disease Who Could Safely and Efficaciously Be Treated With Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2012, 5, 606-617.	1.1	91
255	Distance of Lipid Core-Rich Plaques From the Ostium by NIRS in Nonculprit Coronary Arteries. JACC: Cardiovascular Imaging, 2012, 5, 297-299.	2.3	9
256	Agreement and reproducibility of grayscale intravascular ultrasound and optical coherence tomography for the analysis of the bioresorbable vascular scaffold. Catheterization and Cardiovascular Interventions, 2012, 79, 890-902.	0.7	29
257	Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold. Catheterization and Cardiovascular Interventions, 2012, 79, 880-888.	0.7	38
258	Morphology of coronary artery lesions assessed by virtual histology intravascular ultrasound tissue characterization and fractional flow reserve. International Journal of Cardiovascular Imaging, 2012, 28, 221-228.	0.7	19
259	Quantitative multi-modality imaging analysis of a fully bioresorbable stent: a head-to-head comparison between QCA, IVUS and OCT. International Journal of Cardiovascular Imaging, 2012, 28, 467-478.	0.7	47
260	Evaluation of in-stent restenosis in the APPROACH trial (assessment on the prevention of progression) Tj ETQq0 0 0 rgBT /Overlock 10 T Journal of Cardiovascular Imaging, 2012, 28, 455-465.	0.7	12
261	AS-067 Endothelial-Dependent Vasomotion in Coronary Segment Treated by ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold System is Related to Plaque Composition at the Time of Bioresorption of the Polymer: Indirect Finding of Vascular Reparative Therapy?. American Journal of Cardiology, 2012, 109, S33-S34.	0.7	1
262	AS-125 Distribution of Lipid Core Rich Plaques in Coronary Bifurcations Assessed by Near-Infrared Spectroscopy. American Journal of Cardiology, 2012, 109, S65.	0.7	0
263	AS-301 Lipid Core Burden Index and Framingham Score. American Journal of Cardiology, 2012, 109, S145.	0.7	0
264	Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds: Insights from the ABSORB and SPIRIT trials. Catheterization and Cardiovascular Interventions, 2012, 79, 219-228.	0.7	46
265	Comparison of plaque prolapse in consecutive patients treated with Xience V and Taxus Liberte stents. International Journal of Cardiovascular Imaging, 2012, 28, 23-31.	0.7	10
266	Morphological and functional evaluation of the bioresorption of the bioresorbable everolimus-eluting vascular scaffold using IVUS, echogenicity and vasomotion testing at two year follow-up: a patient level insight into the ABSORB A clinical trial. International Journal of Cardiovascular Imaging, 2012, 28, 51-58.	0.7	19
267	6-Month Clinical Outcomes Following Implantation of the Bioresorbable Everolimus-Eluting Vascular Scaffold in Vessels Smaller or Larger Than 2.5 mm. Journal of the American College of Cardiology, 2011, 58, 258-264.	1.2	44
268	Serial Analysis of the Malapposed and Uncovered Struts of the New Generation of Everolimus-Eluting Bioresorbable Scaffold With Optical Coherence Tomography. JACC: Cardiovascular Interventions, 2011, 4, 992-1001.	1.1	75
269	New Insights Into the Coronary Artery Bifurcation. JACC: Cardiovascular Interventions, 2011, 4, 921-931.	1.1	53
270	Serial In Vivo Intravascular Ultrasound-Based Echogenicity Changes of Everolimus-Eluting Bioresorbable Vascular Scaffold During the First 12 Months After Implantation. JACC: Cardiovascular Interventions, 2011, 4, 1281-1289.	1.1	19

#	ARTICLE	IF	CITATIONS
271	Head-to-Head Comparison of the Neointimal Response Between Metallic and Bioresorbable Everolimus-Eluting Scaffolds Using Optical Coherence Tomography. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 1271-1280.	1.1	61
272	NIRS and IVUS for Characterization of Atherosclerosis in Patients Undergoing Coronary Angiography. <i>JACC: Cardiovascular Imaging</i> , 2011, 4, 647-655.	2.3	76
273	Assessment of Coronary Atherosclerosis Progression and Regression at Bifurcations Using Combined IVUS and OCT. <i>JACC: Cardiovascular Imaging</i> , 2011, 4, 774-780.	2.3	40
274	3D Reconstructions of Optical Frequency Domain Imaging to Improve Understanding of Conventional PCI. <i>JACC: Cardiovascular Imaging</i> , 2011, 4, 1044-1046.	2.3	5
275	Risk of target lesion failure in relationship to vessel angiographic geometry and stent conformability using the second generation of drug-eluting stents. <i>American Heart Journal</i> , 2011, 162, 1069-1079.e2.	1.2	16
276	Cardiovascular risk in obesity: Different activation of inflammation and immune system between obese and morbidly obese subjects. <i>European Journal of Internal Medicine</i> , 2011, 22, 418-423.	1.0	16
277	The SYNTAX Score and SYNTAX-Based Clinical Risk Scores. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2011, 23, 99-105.	0.4	22
278	Impact of Body Mass Index on the Five-Year Outcome of Patients Having Percutaneous Coronary Interventions With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2011, 108, 195-201.	0.7	37
279	Temporal changes of coronary artery plaque located behind the struts of the everolimus eluting bioresorbable vascular scaffold. <i>International Journal of Cardiovascular Imaging</i> , 2011, 27, 859-866.	0.7	21
280	Assessment of drug-eluting stents and bioresorbable stents by grayscale IVUS and IVUS-based imaging modalities. <i>International Journal of Cardiovascular Imaging</i> , 2011, 27, 239-248.	0.7	11
281	Utilizing Risk Scores in Determining the Optimal Revascularization Strategy for Complex Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2011, 13, 415-423.	1.3	14
282	Angiographic Geometric Changes of the Lumen Arterial Wall After Bioresorbable Vascular Scaffolds and Metallic Platform Stents at 1-Year Follow-Up. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 789-799.	1.1	48
283	Expansion of CD4+CD28null T-lymphocytes in diabetic patients: exploring new pathogenetic mechanisms of increased cardiovascular risk in diabetes mellitus. <i>European Heart Journal</i> , 2011, 32, 1214-1226.	1.0	103
284	A comparative assessment by optical coherence tomography of the performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. <i>European Heart Journal</i> , 2011, 32, 294-304.	1.0	58
285	A guide to interpreting and assessing the performance of prediction models. <i>EuroIntervention</i> , 2011, 6, 909-912.	1.4	5
286	Healing of a coronary artery dissection detected by intravascular ultrasound and optical coherence tomography. <i>EuroIntervention</i> , 2011, 7, 288-289.	1.4	2
287	Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: from benchwork to clinical application. <i>EuroIntervention</i> , 2011, 7, 386-399.	1.4	37
288	Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. <i>EuroIntervention</i> , 2011, 7, 977-984.	1.4	41

#	ARTICLE	IF	CITATIONS
289	Adequate antiplatelet regimen in patients on chronic anti-vitamin K treatment undergoing percutaneous coronary intervention. <i>World Journal of Cardiology</i> , 2011, 3, 367.	0.5	1
290	Tools & Techniques: Risk stratification and diagnostic tools in left main stem intervention. <i>EuroIntervention</i> , 2011, 7, 747-753.	1.4	3
291	Baseline C-reactive protein serum levels and in-stent restenosis pattern after m-TOR inhibitors drug-eluting stent implantation. <i>Journal of Invasive Cardiology</i> , 2011, 23, 16-20.	0.4	4
292	Role of the CD14 C(âˆ’260)T promoter polymorphism in determining the first clinical manifestation of coronary artery disease. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 20-25.	0.6	10
293	Background, Incidence, and Predictors of Antiplatelet Therapy Discontinuation During the First Year After Drug-Eluting Stent Implantation. <i>Circulation</i> , 2010, 122, 1017-1025.	1.6	98
294	Long-Term Clinical Outcome Based on Aspirin and Clopidogrel Responsiveness Status After Elective Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1447-1455.	1.2	118
295	Paradoxical Preservation of Vascular Function in Severe Obesity. <i>American Journal of Medicine</i> , 2010, 123, 727-734.	0.6	70
296	Diabetes mellitus: a prothrombotic state. Implications for outcomes after coronary revascularization. <i>Vascular Health and Risk Management</i> , 2009, 5, 101.	1.0	11
297	Zotarolimus for the treatment of coronary artery disease: pathophysiology, DES design, clinical evaluation and future perspective. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1047-1058.	0.9	18
298	Gene expression profiles in peripheral blood mononuclear cells of chronic heart failure patients. <i>Physiological Genomics</i> , 2009, 38, 233-240.	1.0	68
299	Delayed neutrophil apoptosis in patients with unstable angina: relation to C-reactive protein and recurrence of instability. <i>European Heart Journal</i> , 2009, 30, 2220-2225.	1.0	28
300	Outcome of patients treated by a novel thinâ€strut cobaltâ€chromium stent in the drugâ€eluting stent era: Results of the SKICE (Skylor in real world practice) registry. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 457-465.	0.7	11
301	Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention. <i>Circulation</i> , 2009, 119, 3215-3222.	1.6	213
302	Effect of intensive vs standard statin therapy on endothelial progenitor cells and left ventricular function in patients with acute myocardial infarction: Statins for regeneration after acute myocardial infarction and PCI (STRAP) trial. <i>International Journal of Cardiology</i> , 2008, 130, 457-462.	0.8	69
303	Cystatin C is associated with an increased coronary atherosclerotic burden and a stable plaque phenotype in patients with ischemic heart disease and normal glomerular filtration rate. <i>Atherosclerosis</i> , 2008, 198, 373-380.	0.4	55
304	1059G/C polymorphism within the exon 2 of the C-reactive protein gene: relationship to C-reactive protein levels and prognosis in unstable angina. <i>Coronary Artery Disease</i> , 2007, 18, 533-538.	0.3	12
305	Persistent Activation of Nuclear Factor Kappa-B Signaling Pathway in Patients With Unstable Angina and Elevated Levels of C-Reactive Protein. <i>Journal of the American College of Cardiology</i> , 2007, 49, 185-194.	1.2	91
306	Unusual CD4+CD28nullT Lymphocytes and Recurrence of Acute Coronary Events. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1450-1458.	1.2	214

#	ARTICLE	IF	CITATIONS
307	Usefulness of Granulocyte Colony-Stimulating Factor in Patients With a Large Anterior Wall Acute Myocardial Infarction to Prevent Left Ventricular Remodeling (The Rigenera Study). American Journal of Cardiology, 2007, 100, 397-403.	0.7	55
308	Modulation of CD4 + CD28 null T Lymphocytes by Tumor Necrosis Factor- $\alpha$ Blockade in Patients With Unstable Angina. Circulation, 2006, 113, 2272-2277.	1.6	61
309	C-Reactive Protein and Other Inflammatory Biomarkers as Predictors of Outcome Following Acute Coronary Syndromes. Seminars in Vascular Medicine, 2003, 03, 375-384.	2.1	32